<DOC>
	<DOCNO>NCT01206062</DOCNO>
	<brief_summary>Elevated blood pressure ( BP ) important public health concern . It highly prevalent , prevalence may increase , risk factor several adverse health outcome , especially coronary heart disease , stroke , heart failure , chronic kidney disease , decline cognitive function . The Systolic Blood Pressure Intervention Trial ( SPRINT ) 2-arm , multicenter , randomize clinical trial design test whether treatment program aim reduce systolic blood pressure ( SBP ) low goal currently recommend reduce cardiovascular disease ( CVD ) risk .</brief_summary>
	<brief_title>Systolic Blood Pressure Intervention Trial</brief_title>
	<detailed_description>SPRINT randomize 9250 participant age ≥ 50 year SBP ≥130 mm Hg least one additional CVD risk factor . The trial compare effect randomization treatment program intensive SBP goal randomization treatment program standard goal . Target SBP goal &lt; 120 v &lt; 140 mm Hg , respectively , create minimum mean difference 10 mm Hg two randomize group . The primary hypothesis CVD event rate lower intensive arm . Participants recruit approximately 90 clinic within 5 clinical center network ( CCNs ) approximately 2-year period , follow 4-6 year .</detailed_description>
	<criteria>At least 50 year old Systolic blood pressure 130 180 mm Hg 0 1 medication 130 170 mm Hg 2 medication 130 160 mm Hg 3 medication 130 150 mm Hg 4 medication Risk ( one follow ) 1 . Presence clinical subclinical cardiovascular disease stroke 2 . CKD , define eGFR 20 59 ml/min/1.73m2 3 . A Framingham Risk Score 10year CVD risk ≥ 15 % 4 . Age great 75 year An indication specific BP lower medication person take person document intolerant medication class . Known secondary cause hypertension cause concern regard safety protocol . One minute stand SBP &lt; 110 mm Hg . Proteinuria follow range ( base measurement within past 6 month ) 24 hour urinary protein excretion ≥1 g/day , 24 hour urinary albumin excretion ≥ 600 mg/day , spot urine protein/creatinine ratio ≥ 1 g/g creatinine , spot urine albumin/creatinine ratio ≥ 600 mg/g creatinine , urine dipstick ≥ 2+ protein Arm circumference large small allow accurate blood pressure measurement available device Diabetes mellitus , History stroke ( CE stenting ) Diagnosis polycystic kidney disease Glomerulonephritis treat likely treat immunosuppressive therapy eGFR &lt; 20 ml/min /1.73m2 endstage renal disease ( ESRD ) Cardiovascular event procedure ( defined clinical CVD study entry ) hospitalization unstable angina within last 3 month Symptomatic heart failure within past 6 month leave ventricular ejection fraction ( method ) &lt; 35 % A medical condition likely limit survival le 3 year malignancy nonmelanoma skin cancer within last 2 year Any factor judge clinic team likely limit adherence intervention . Failure obtain informed consent participant Currently participate another clinical trial ( intervention study ) . Note : Patient must wait completion his/her activity completion trial screen SPRINT . Living household already randomize SPRINT participant Any organ transplant Unintentional weight loss &gt; 10 % last 6 month Pregnancy , currently try become pregnant , childbearing potential use birth control .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>blood pressure</keyword>
	<keyword>antihypertensive</keyword>
	<keyword>systolic</keyword>
	<keyword>diastolic</keyword>
	<keyword>heart failure</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>stroke</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>dementia</keyword>
	<keyword>cognitive decline</keyword>
</DOC>